NYU Doctors Explain DCIS

Article

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

They explain what DCIS is, discuss public trials and future directions for DCIS, and address some current controversies around the diagnosis.

Listen to the talk here:

Recent Videos
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Anatomical rendering of the female reproductive system with a tumor in the uterine lining

Palbociclib Plus Letrozole May Increase PFS for ER+ Endometrial Cancer

Ashley Chan
March 14th 2025
Article

Palbociclib plus letrozole lengthened PFS vs placebo plus letrozole for patients with ER-positive advanced or recurrent endometrial cancer.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Photo of someone in a white lab coat writing on a clipboard with a stethoscope on it.

Toxicity May Be Underreported in Phase 3 Oncology Trials

Bridget Hoyt
March 12th 2025
Article

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Anatomical rendering of the gastrointestinal tract with the colon highlighted in yellow

Panitumumab Combo Elicits Response in mCRC Subset

Bridget Hoyt
March 11th 2025
Article

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark.

Illustration of small patient and provider characters surrounded by larger technology devices with medical information coming off of the screens and other medical props nearby

Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence

Bridget Hoyt
March 10th 2025
Article

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.